n(1)-methylnicotinamide has been researched along with Graves Disease in 1 studies
N(1)-methylnicotinamide: RN given refers to parent cpd
1-methylnicotinamide : A pyridinium ion comprising nicotinamide having a methyl group at the 1-position. It is a metabolite of nicotinamide which was initially considered to be biologically inactive but has emerged as an anti-thrombotic and anti-inflammatory agent.
Graves Disease: A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Filetti, S | 1 |
| Takai, NA | 1 |
| Rapoport, B | 1 |
1 other study available for n(1)-methylnicotinamide and Graves Disease
| Article | Year |
|---|---|
Prevention by nicotinamide of desensitization to thyrotropin stimulation in cultured human thyroid cells.
Topics: Cells, Cultured; Cyclic AMP; Cycloheximide; Drug Synergism; Graves Disease; Humans; Kinetics; Niacin | 1981 |